Korean Market
EXCH
Pharos iBio
★

Pharos iBio Adjusts Conversion Price to 8,000 KRW for 1st Series CB Due to Market Decline; Potential Dilution Rises

 
OWNR
Pharos iBio
★

Pharos iBio CEO Jeonghyeok Yoon Increases Stake to 21.43% with 15,000 Share Open Market Purchase, Signaling Confidence

 
EXCH
Pharos iBio
★★

Pharos iBio Selected for Government AI Drug Development Project: 3.52B KRW Non-Dilutive Funding for Next-Generation EGFR-Resistant NSCLC Treatment, Positive for Shareholder Value

 
PERI
Pharos iBio
★

Pharos iBio Q1 2026: PHI-101 Phase 1 Complete, Operating Loss Continues, Convertible Bond Burden